Natriuretic peptides, including BNP and NT-proBNP, are widely recognized as essential biomarkers for diagnosing and managing heart failure. However, their clinical utility extends far beyond traditional heart failure settings. Secreted by cardiomyocytes in response to myocardial stretch, these peptides offer valuable insight into a range of cardiopulmonary and metabolic conditions. This webinar will explore the expanding role of BNP and NT-proBNP in both outpatient and inpatient care, including their application in pulmonary arterial hypertension (PAH) and acute pulmonary embolism (PE).
Learning Objectives:
- Describe how natriuretic peptides contribute to risk stratification, treatment decisions, and disease monitoring.
- Illustrate how to interpret elevated values in different clinical contexts, including stable outpatient management of pulmonary arterial hypertension (PAH) and acute triage decisions in the emergency department for acute pulmonary embolism (PE).
- Discuss current recommendations from recent global clinical guidelines and symposiums.
- Explain how medications influence NT-proBNP levels and how they can guide the optimization of treatment to reduce hospitalization and mortality rates in patients with heart failure.
Educational support provided by
